Company: CDT
Filing Date: 2025-01-14
Form Type: 8-K
Source: 0001493152-25-002176
Chunk: 0

Company: CDT Equity Inc.
Filing Date: 2025-01-14
Form: 8-K
Item: Item 5.07
Chunk 0
---
Item
5.07. Submission of Matters to a Vote of Security Holders.

On
January 9, 2025, Conduit Pharmaceuticals Inc. (the “ Company”), convened a special meeting of stockholders (the “ Special
Meeting”). The Company adjourned the meeting until 10:00 a. m. Eastern Time on January 13, 2025.

The
Company reconvened the Special Meeting on January 13, 2025. Proxies had been submitted by stockholders representing over one-third of
the shares of the Company’s common stock outstanding and entitled to vote, which constituted a quorum. At the Special Meeting,
the Company’s stockholders voted on three proposals, each of which is described in more detail in the proxy statement.

The
following is a brief description of each matter voted upon and the results, including the number of votes cast for and against each matter
and, if applicable, the number of abstentions and broker non-votes with respect to each matter. Proxies for the Special Meeting were
solicited pursuant to Section 14(a) of the Securities Exchange Act of 1934, as amended, and there was no solicitation in opposition of
management’s solicitation.

Proposal
No. 1

   Votes For      Votes Against      Abstentions      Broker Non-Votes  
 ────────────────────────────────────────────────────────────────────────
  38,067,839          1,540,659          368,985                     0  

Proposal
No. 2

   Votes For      Votes Against      Abstentions      Broker Non-Votes  
 ────────────────────────────────────────────────────────────────────────
  35,000,998          4,608,682          367,802                     0  

Proposal
No. 3

   Votes For      Votes Against      Abstentions      Broker Non-Votes  
 ────────────────────────────────────────────────────────────────────────
  35,013,951          4,596,139          367,392                     0  

SIGNATURES

Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.

  Date:                 CONDUIT                                      
  January 14, 2025      PHARMACEUTICALS INC.                         
 ─────────────────────────────────────────────────